Skip to main content
Sign In
 

Clinical Trials

Volunteer to Be Part of a Research Study


Page through all School of Medicine clinical and research trials below. There are two categories: 

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please submit your Web ad here.  

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 4, items 1 to 30 of 109.
COMIRB Approved Advertisement TitleStudy GoalsEligibility CriteriaDate Posted
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 4, items 1 to 30 of 109.
Investigations in Gestational Origins of Lifetime Development: Understanding health begins before birth. Are you in your first trimester of Pregnancy?
To learn more about how your metabolism is connected to your baby's growth and development
Healthy Women ages 18-35 who are 10-14 weeks pregnant with single baby.  Norm BMI or 30-38 who are willing to complete 5 visits during pregnancy and agreeable to an infant blood draw at birth and DXA postpartum.  Delivery must be at University of Colorado Hospital.  there is an option to take part in a 1 year follow-up which entails an additional 4 visits and another DXA at 1 year of life.
10/1/2014
We are Currently Enrolling People with Down syndrome for a study in Dr. Pelak's Brain and Vision Research lab at the University of Colorado Anschutz Medical Campus.
To examine visual brain function in people with mild memory impairments to detect early signs of Alzheimer's Disease.​
Persons 19-30 who have Down Syndrome
10/1/2014
You are invited to participate in EMERALD, as research study about Metformin and Type 1 Diabetes in Adolescents
​To determine the effects of Metformin on Cardiovascular Function in Adolescents with Type 1 Diabetes.
Persons 12-21 who have Type 1 Diabetes, non-smoker and exercise no more than 3 hours a week.  You must be willing to take metformin or placebo (sugar pill) for 3 months.   Other exclusions apply, please contract study for more information
10/1/2014
Children's Hospital, department of Pediatric Neurology is conducting a research study
Evaluating the effects of a single treatment of injected BOTOX® (Botulinum Toxin Type A) for chronic migraine(s) in adolescents.
Adolescents 12-17 who have no serious medical conditions but have at least 15 headaches a month for the last 6 months. You not have any previous BOTX treatments or are not currently using any prophylactic medicine.
10/1/2014
Non-Alcoholic Fatty Liver Disease and Obstructive Sleep Apnea: Mechanistic Links between Hypoxemia and Liver Injury
To learn if obstructive sleep apnea and low oxygen levels have a role in developing Non-Alcoholic Fatty Liver Disease (NAFLD).​​​
Children 10-17 who have a normal weight and no serious medical problems
10/1/2014
Are you using Implanon or Nexplanon for birth control?
Study on a potential treatment for bothersome bleeding/spotting related to the etonogestrel implant.
Women 18-44 who are experiencing bothersome bleeding/spotting while using Implanon or Nexplanon
10/1/2014
Exercise and Cancer Prevention Research Study
The goal of this study is to better understand the biological mechanisms associated with exercise and reduced risk for breast cancer.
You must be a female between the ages of 30-45 to participate in this study. You must be planning to live in the Denver metropolitan area for the next 10 consecutive months. You should not be a regular exerciser because this study is for people who do not exercise right now; however, you should be willing to participate in an exercise program 4 times per week for 16-weeks.
10/1/2014
Are you interested in a supervised exercise intervention?
Volunteers are needed for a research study to examine the effects of exercise on food intake and appetite regulation.
- 21-45 years old - Non- smoker - Non- Diabetic - Exercise no more than 1 time a week - Maintained your current weight for last 6 months - Have a body mass index (BMI) of 27-35 (check it out at http://nhlbisupport.com/bmi/)
10/1/2014
Study of Mood Disorder in Preschool Children
We are doing a research study to better understand what mood disorders look like in preschool children.
We are looking for volunteers who:   *    Are parents of children between the ages of 4 and 6 years 0 months.  *    Are in one of three groups:         1) Their child has no major mental health problems, and there is            no family history of major mood or psychotic disorders.          2) Their child has been diagnosed with a mood disorder, bipolar disorder, or              mood dysregulation disorder.  3) Their child has been diagnosed with attention deficit hyperactivity  disorder (ADHD).  Parents or guardians will be asked to:                *    Read and sign a consent form               *    Participate in interviews about their children. The  children will be asked to:    *    Participate in a story game    *    Take tests of verbal and nonverbal abilities   How much time will this take? The visit for the child will last from 1 to 2 hours.  The visit for the parents will last 3 to 5 hours.
10/1/2014
MRI and Questionnaire Research Study for Patients with MS Taking Tysabri and Healthy Controls
This research study plans to learn more about the differences in brain scans and self-reported quality of life between MS patients taking natalizumab (Tysabri) and individuals without MS.
-A relapsing Multiple Sclerosis patient 18-55 years old who has been taking Tysabri (natalizumab) for at least 2 years OR -A healthy individual 18-55 years old without Multiple Sclerosis or other neurological conditions
10/1/2014
Understanding how Tysabri and Gilenya Influence the Quality of your Daily Life with Multiple Sclerosis
The purpose of this research study is to compare two medications, Tysabri and Gilenya, used in the treatment of multiple sclerosis (MS), through a few self reported patient surveys. We will ask you to complete online surveys about overall health-related quality of life, disability, fatigue, cognition and productivity. We will also want to review your medical records to understand your MS history with your permission. This study will help us understand how these drugs are impacting each aspect of your daily lives.
-Between ages 16 and 65 -Scheduled to start natalizumab or fingolimod for the first time to treat your MS
10/1/2014
Brown Adipose Tissue and Estrogen (BATE Study)
To investigate whether estrogen influences the activity of brown adipose tissue.
Healthy non-smoking women 20-40 who have regular menstrual cycles and are not on hormonal contraceptives and exercise more than once per week
9/30/2014
Type 2 Diabetes and Exercise Research Study
Perceived exertion during exercise
Person 50-70 with or without Type 2 diabetes who exercise vigorously less than one hour per week and have normal blood pressure.  You should have a BMI between 25-35 and have not smoked for a least one year.
9/30/2014
Is your child 6-18 years old and interested in participating in a research study?
To study the effects of polycystic kidney disease (PKD) on blood vessel function
Children 6-22 free from kidney disease and other chronic diseases
9/30/2014
Evaluation of Glucose Sensor and Insulin Infusion Set Failures: Lipohypertrophy Study
This study is looking at evaluating Insulin Pump Infusion sites and Continuous Glucose Monitoring sites in tissue with Lipohypertrophy. We will also be looking at using the sites for a longer duration.
Lipohypertrophy site of 3 cm or greater in diameter Ages 12-45 inclusive A1C Value of < 10% Insulin pump use of at least 3 month duration Pump use with Medtronic, Animas or T-slim Willing to wear two CGM's during the 4 weeks of the study
9/30/2014
Are you trying to lose weight?
Volunteers needed for a research study about the weight loss medication Phentermine  
Healthy and between 30-45 years of age •Have a BMI between 30 and 40 (calculate your BMI at http://www.nhlbisupport.com/bmi/) •Willing to take the weight loss medication Phentermine for a period of 8 weeks (but not currently taking any approved or investigational medication for weight loss)
9/30/2014
Participants Ages 12-15 years old Needed for Research Study
To learn about how children with absence epilepsy compare to healthy children in areas such as behavior, neuropsychological skills and quality of life.
Healthy hispanic individuals who are 12-15 years; No history of seizures, seizure like episodes, neurological diseases or a loss of consciousness greater than 5 minutes in their immediate family
9/30/2014
University of Colorado is looking for Pregnant Women to participate in a text messaging and Facebook research study.
The University of Colorado is doing a research study to learn how best to deliver text messages and social media that encourage pregnant women to breastfeed.
Females 18-40 who can speak and write in English or Spanish  You must be at least 36 weeks pregnant and have access to a mobile device that can receive text messages and has access to the Internet (smart phone).
9/30/2014
Healthy Hispanic Female Adolescents Needed!!!
For brain imaging research study on how the brain works with we taste sweets or receive money. Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity.
Healthy females 11 to 21 who are right-handed, free of medication with no serious medical conditions or permanent metal implants or braces/retainers and are at a healthy body weight.
9/30/2014
Are you stopping your birth control because you want to become pregnant?
To look at contraception rates after birth control discontinuation.
Women 18-35 who are planning to, or have recently stopped their birth control because they want to become pregnant.
9/29/2014
Healthy Postmenopausal Women needed to participate in a research study
To test whether estrogen has different effects on blood sugar early in menopause compared to many years after menopause​.​
Women 45-70 who have gone through menopause within the past 6 years or are more than 10 years past menopause, never used hormone therapy for more than 6 months and are willing to use estrogen patches for 1 week.  Must be a non-smoker and sedentary to moderately active.
9/29/2014
Type 1 Diabetes Research Study
To study the effects of a medication on metabolism and blood vessel function.
Persons 25-50 years old with or without type 1 diabetes with normal blood pressure and exercise vigorously no greater than 3 times per week.
9/29/2014
JUST DIAGNOSED WITH SHINGLES?
This study will look at the body's immune response (how the body fights infection) to the onset of shingles. 1-2 study visits for blood draws, over the course of 3 months.
18+ years of age; NO PRIOR HISTORY of shingles; have NEVER received the shingles vaccine; have DEVELOPED SHINGLES within the last 10 days.
9/29/2014
Shingles Vaccine Clinical Research Trial
This study will compare responses to two shingles vaccines - the current FDA approved shingles vaccine and an investigational shingles vaccine in younger and older people.
50-59 years of age or 70-85 years of age; General good health; No prior history of shingles; Have never received the shingles vaccine; although... a subset of 70-85 year olds who DID receive the shingles vaccine at least 5 years previously is also needed (must be able to provide documentation of vaccination)
9/29/2014
protein and infant growth: Do you have a child younger than 6 months
Participants in this research study on protein from complementary foods (meat or dairy) and infant growth, will learn how protein consumption affects your child’s growth, fat gain, and gut health from 6 to 12 months of age.  
To qualify, you child needs to be: 1. Formula fed, or not on breast-milk longer than 1 month. 2. Younger than 6 months. 3. Generally healthy. You will receive commercially available complementary foods for 7 months, Receive infant formula at no cost for 7 months, You will know your child's body fat and fat free mass and blood lipid level.
9/29/2014
Volunteers Needed: Thinking and Memory in Parkinson's Disease
This research study aims to better understand how changes in brain activity may be related to thinking problems in Parkinson's Disease and to determine whether, by stimulating certain areas, thinking and memory can be improved.
Person's with Parkinson's Disease with mild thinking and memory problems. Between 40-90 years old. No metal in your body. No implant. Not taking any medication to improve memory. Not taking stimulants or seizure medication.
9/29/2014
Research Participants Needed
We are looking for participants with diabetes to serve as a standard for comparison when describing physical function outcomes before and during prosthetic rehabilitation.
Inclusion Criteria: 1) 50-85 years of age. 2) Able to walk continuously without assistance (i.e., do not use a cane or walker) for 10 minutes and physically active (e.g., participate in recreational activities like walking, jogging, hiking). 3) Diagnosis of diabetes. 4) No other neurological, vascular or cardiac problems that limit function. 5) Body mass index
9/29/2014
HAVE YOU OR YOUR CHILD BEEN DIAGNOSED WITH ASTHMA?
We are looking for volunteers to participate in an N.I.H. funded research study.
Children 12 years of age and older and non-smoking Adults who have mild to moderate asthma who are not currently taking inhaled steroid medication
9/29/2014
Diabetic Male and Female Volunteers Needed for Exercise Research Study
Evaluate exercise function during single leg calf exercise in people with or without type 2 diabetes
Healthy Adults 30-70 with Type 2 diabetes but not using insulin.  Must be a non-smoker who exercise no more than one time per week and have a BMI of 25-40
9/26/2014
Trouble Controlling your Type 2 Diabetes?
Investigational non-surgical device that may help decrease blood sugar.
Adults 21-65 with type 2 Diabetes and not on oral medication, not taking insulin. Must have an A1C level of 8-10%, be overweight or obese and willing to attend study visits
9/26/2014

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 16, items 1 to 30 of 461.
Protocol TitlePI NameInstitution Number
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 16, items 1 to 30 of 461.
Eisenmenger Quality Enhancement Research Initiative (QuERI). Sponsor Protocol 20111728. WIRB Protocol No. 20111728
Kay, Joseph12-0926
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Two Doses of Subcutaneous Pulsatile GnRH Administered via OmniPod Pump for Ovulation Induction in Female Subjects with Primary Amenorrhea with Hypogonadotropic Hypogonadism. Sponsor Protocol No. 000070. WIRB Protocol No. 20140452
Santoro, Nanette13-2352
A Phase 1b, multi-center, two parallel group, open-label, drug-drug interaction study to assess the effect of LDE225 on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumors. Sponsor Protocol No. CLDE225A2112. WIRB Protocol No.20130681
Lewis, Karl13-2556
A Randomized Phase 2 Study of Oral AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Been Treated with Crizotinib. Sponsor Protocol No. AP26113-13-201. WIRB Protocol No.20131562
Camidge, David13-2648
A MULTI-CENTER,OPEN LABEL, FIRST IN HUMAN, PHASE I DOSE ESCALATION STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO6839921, AN MDM2 ANTAGONIST FOLLOWING INTRAVENOUS ADMINISTRATION IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ACUTE MYELOID LEUKEMIA (AML). Sponsor Protocol No. NP28903. WIRB Protocol No. 20140542
Gore, Lia13-2649
A 12-Week Multicenter, Randomized, Double-Blind,Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period. Sponsor Protocol No. I1F-MC-RHBC(b). WIRB Protocol No. 20121432
Armstrong, April13-2723
A PHASE II, RANDOMIZED STUDY OF MPDL3280A ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA. Sponsor Protocol No. WO29074. WIRB Protocol No. 20131502
Lam, Elaine13-2806
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor-Positive and HER2-Normal. Sponsor Protocol No. MDV3100-12. WIRB Protocol No. 20131280
Elias, Anthony13-2892
A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM). Sponsor Protocol No. 109MS401. WIRB Protocol No. 20140071
Schreiner, Teri13-2897
A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX-2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Sponsor Protocol No. VRXP-A202. WIRB Protocol No. 20131627
Jimeno, Antonio13-2911
A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure. Sponsor Protocol No. E5501-G000-311. WIRB Protocol No. 20131907
Everson, Greg13-2914
A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcinerurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation- Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM). Sponsor Protocol No. CRAD001A2433. WIRB Protocol No. 20140590
Wiseman, Alexander13-2918
PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer. Sponsor Protocol No. MDV3100-14. WIRB Protocol No. 20131112
Crawford, E13-2937
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy. Sponsor Protocol No. D0816C00002. WIRB Protocol No. 20131789
Davidson, Susan13-2969
A Phase 1b, open-label study to assess the safety and tolerability of ONT-380 combined with capecitabine and trastuzumab, alone and in combination in HER2+ metastatic breast cancer. Sponsor Protocol No. ONT-380-005. WIRB Protocol No. 20140127
Borges, Virginia13-3000
A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination with Abiraterone in Chemotherapy Naïve Subjects with Bone-Metastatic Castration-Resistant Prostate Cancer. Sponsor Protocol No. XL184-210. WIRB Protocol No. 20140076
Flaig, Thomas13-3004
A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women. Sponsor Protocol No. V98_12. WIRB Protocol No. 20140324
Gibbs, Ronald13-3019
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome. Sponsor Protocol No. Neu-2566-FXS-001. WIRB Protocol No. 20132053
Tartaglia, Nicole13-3117
Evaluation of Acute Rejection Rates in de novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (belatacept) -based Immunosuppression. Sponsor Protocol No, IM103177. WIRB Protocol No. 20132295
Wiseman, Alexander13-3123
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected with Human Immunodeficiency Virus (HIV). Sponsor Protocol No. AI444216. WIRB Protocol No. 20140021
Campbell, Thomas13-3250
A Multi-Center, Multi-National Clinical Study to Evaluate the Safety and Effectiveness of the Essure® (Model ESS505) Device to Prevent Pregnancy in Women Who Are Seeking Permanent Contraception. Sponsor Protocol No. 16973. WIRB Protocol No. 20140151
Tocce, Kristina13-3258
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF 3-MONTH SUBCUTANEOUS REGN1033 TREATMENT IN PATIENTS WITH SARCOPENIA. Sponsor Protocol No. R1033-SRC-1239. WIRB Protocol No.20131518
Schwartz, Robert13-3265
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation Sponsor Protocol No. AG120-C-002 WIRB Protocol No. 20140544
Gore, Lia14-0012
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation. Sponsor Protocol No. AG120-C-001. WIRB Protocol No. 20140421
Pollyea, Daniel14-0013
A Phase Ib dose escalation/randomized phase II multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. Sponsor Protocol No. CBYL719X2104. WIRB Protocol No.20140692
Jimeno, Antonio14-0034
A safety study for MSB0010445 in combination with Stereotactic Body Radiation in advanced melanoma subjects following prior treatment with ipilimumab Sponsor Protocol No. EMR 062235-005 WIRB Protocol No. 20140683
Lewis, Karl14-0050
Phase 1 study of ONT-10, a liposomal MUC1 cancer vaccine, in patients with solid tumors. Sponsor Protocol No. ONT-10-001. WIRB Protocol No. 20140202
Borges, Virginia14-0063
Maintenance therapy with ONT-10, a liposomal MUC1 cancer vaccine, in patients who have previously received ONT-10. Sponsor Protocol No. ONT-10-002. WIRB Protocol No. 20140221
Borges, Virginia14-0064
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer. Sponsor Protocol No. 18R5-002. WIRB Protocol No. 20140743
Diamond, Jennifer14-0065
International, multicenter, open-label, treatment-extension study for subjects who completed a Phase 1 or Phase 2 parental study to continue receiving treatment with SAR245408 or SAR245409 as a monotherapy or as a combination regimen. Sponsor Protocol No. TED12414. WIRB Protocol No. 20120931
Gore, Lia14-0079